• Marcus Kuhnert will step down as Chief Financial Officer and Member of the Executive Board after a successful nine-year tenure
• Helene von Roeder appointed Chief Financial Officer and Executive Board Member, effective July 1, 2023

Darmstadt, Germany – Marcus Kuhnert has decided to step down as Chief Financial Officer and Member of the Executive Board of Merck as of June 30, 2023. He will continue to serve as a Member of the Executive Board of E. Merck KG until July 31, 2024. The Board of Partners of E. Merck KG has appointed Helene von Roeder as the new Chief Financial Officer and Member of the Executive Board of Merck as of July 1, 2023.

“Marcus Kuhnert’s leadership, dedication and business acumen served to secure the strong financial position of the Group, and ensure we were well poised to seize transformative opportunities, which have made Merck larger, stronger, and bolder. We thank him for his tremendous contribution and wish him well in this next phase of his journey,” said Johannes Baillou, Chairman of the Board of Partners of E. Merck KG.

Helene von Roeder will join the Executive Board of Merck, effective July 1, 2023. She will be located in Darmstadt, Germany. She joins Merck from Vonovia SE where she served as Chief Financial Officer until 2021, and then transitioned to become Chief Transformation Officer, both as a Member of the Executive Board. Prior to that, she spent 23 years working in London, UK, and Frankfurt, Germany, at various investment banks, among others as Chief Executive Officer of Credit Suisse, Germany, Austria and Central and Eastern Europe (CEE), and prior to that as Head of Global Capital Markets for Germany and Austria at Morgan Stanley.

The German national studied theoretical physics at the Ludwig Maximilian University of Munich, Germany, and went on to receive a Master’s Degree of Philosophy in theoretical astrophysics at the University of Cambridge, UK.

Helene von Roeder was a Member of the Merck Supervisory Board and Board of Partners of E. Merck KG since 2019, serving as Chair of the Audit and Finance committees, respectively. As part of the new assignment, she has resigned from these positions.

“We look forward to welcoming Helene von Roeder to Merck in this new capacity. She brings with her extensive experience in investment banking, capital markets and the broader financial industry, alongside a natural scientific curiosity as a physicist. Her longstanding relationship with Merck, and the insight she has gained working as part of our Board structure, will ensure continued stability, and make the transition seamless,” said Johannes Baillou.

All other Executive Board Members will continue to pursue their current responsibilities. As of July 2023, the Executive Board of Merck will be structured as follows:

Belén Garijo, Chair of the Executive Board and CEO
Board responsibility for Group functions Global Communications & Stakeholder Engagement / Corporate Sustainability, Quality and Trade Compliance / Human Resources / Internal Auditing / Legal & Compliance / Strategy, M&A & Venturing / Science & Technology Office

Kai Beckmann, Member of the Executive Board
CEO Electronics and Board responsibility for Group functions Inhouse Consulting / Patents & Scientific Information / Site Management

Peter Guenter, Member of the Executive Board
CEO Healthcare and Board responsibility for Group Global Health, Bioethics and Digital Ethics

Matthias Heinzel, Member of the Executive Board
CEO Life Science

Helene von Roeder, Member of the Executive Board
Chief Financial Officer and Board responsibility for Group functions Information Technology / Procurement / Merck Business Services

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.